Conor Lane

@MayoClinicCV Fellow 🫀 | @MayoMN_IMRES alumnus | Structural/Interventional | Opinions my own 🇮🇪🇺🇸

[Mack Eleid @EleidMack]

Congrats to our graduating SHD interventional fellows- proud of you! The future is bright @MayoClinicCV @MayoCVFellows

[Mahmoud Ismayl, M.D. @Mahmoud_Ismayl]

Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows

[Conor Lane @DrConorLane]

Incredible weekend at #TCT2025! Grateful to be able to present our center's experience with novel approaches to coronary aneurysm management, and to be named among the best in show! Thankful to @rajivxgulati for his innovation and mentorship

[Mayra Guerrero, MD @MayraGuerreroMD]

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone that will not only transform the field of interventional cardiology but, most importantly, will change the lives of countless patients who have been waiting for a viable treatment option. Slides presented as LBCT #TCT2025 today and link to our manuscript published @TheLancet today are included. Thank you to all the people who worked with us for a decade to make this happen! @DVDaniels @MayoClinicCV

https://t.co/ufEseWlevp

[Mohamad Alkhouli @adnanalkhouli]

The 10-year outcome of Noble trial may be the most impactful data presented at #TCT2025

PCI=CABG for isolated left main disease regardless of Syntax score

Which isolated LM patients (suitable for PCI) will you refer to CABG?

[Mayo Clinic Cardiac Surgery @MayoClinicCVS]

The @MayoClinicCV & @MayoClinicCVS partners w/leading institutions in Mexico to perform North America’s first Silara MiBridgeTransseptal Direct Mitral Annuloplasty! Our groundbreaking Mayo team included Drs. Mayra Guerrero, Kimberly Holst, Sari Padang & Sorin Pislaru.

[Brenden Ingraham, M.D. @BrendenIngraham]

Genotype-Guided P2Y12i Monotherapy Within 7 Days of PCI in High Bleeding Risk Patients: The CHAMP Trial - Pilot Study & Safety Assessment

📝Genotype-guided P2Y12 inhibitor monotherapy within a week of PCI is feasible and likely safe in patients with HBR.

https://t.co/d4KK5gjAxm

[Rajiv Gulati @rajivxgulati]

🎈Expanding LM bifurcation aneurysm
🎈Use of neuro web device
🎈#RadialFirst
🎈Hugely fortunate to work with and learn from talented colleagues @WBrinjikji @DrConorLane @MayoClinicCV

[Mayra Guerrero, MD @MayraGuerreroMD]

We evaluated 820 patients treated with TS MViR using the Sapien 3/Ultra/RESILIA THVs between Aug 2015 and Dec 2022 who were enrolled in the STS/ACC TVT Registry. We found a significant reduction in MR and sustained improvement in symptoms at 1 year. Mean mitral gradients were elevated at 30 days (7.9 ± 3.0 mmHg) and at 1 year (8.4 ± 3.4 mmHg), and reintervention rate was high at 1 year (9.1%). However, there was a significant improvement in quality of life which was sustained at 1 year (mean KCCQ score improvement at 30-day was 24.1 points and at 1 year was 25.9). TS MViR is a reasonable alternative for high-risk patients unable to undergo surgery who have favorable anatomy for MViR procedure. @MayoClinicCV
Contemporary 1-Year Outcomes of Mitral Valve-in-Ring With Balloon-Expa... https://t.co/yf3LbDBpwB

[FITsOnTheGo @FITsOnTheGo]

🔍 Exciting findings from the AEGIS-II Trial are in! 🎉 Discover how this breakthrough therapy could redefine cardiovascular care with @CMichaelGibson💪
@accintouch @mayoclinic @DrConorLane @BaimInstitute
#ACC2024 #ACCFIT #CardioTwitter

https://t.co/1uGiK4lOKG

[Conor Lane @DrConorLane]

What a privilege to learn from some of the best in the business at #Fellows2024! Thanks again to @crfheart and all the faculty for this fantastic opportunity.

[Cardiovascular Research Foundation @crfheart]

🎉 #Fellows2024 was a great success! 🎉Thank you to all our attendees, supporters, course directors, and faculty for making it a memorable and enriching experience! 🙌 https://t.co/mcYzTMbRs8

#CardioEd @djc795 @jgranadacrf @MartyBLeon @mbmcentegart @Drroxmehran @sahilparikhmd @triciarawh

[JACC Journals @JACCJournals]

Check out this #JACCINT state-of-the-art review discussing the contemporary assessment and management of tricuspid regurgitation https://t.co/rHBUbPcGgG

#vhdTR #CathLab @GarrettWelleMD @EleidMack @hahn_rt

[Mayo Clinic Rochester Cardiology Fellows @MayoCVFellows]

The @MayoCVFellows family hanging out at @ACCinTouch #ACC24! A 💪🏻 first conference day, with countless presentations, posters, interviews, smiles, hugs, and general mischief 💓! Say hi if you see us! @MayoClinicCV @MayoClinic @FITsOnTheGo

[Brenden Ingraham, M.D. @BrendenIngraham]

@mandeep_mayo presents our findings from the CHAMP Trial. #Genotype-guided P2Y12 inhibitor monotherapy within a week of #PCI is feasible and likely safe in patients with #HBR. @rajivxgulati @ChetRihal @LermanAmir @nl_pereira @LinneaBaudhuin @AnnMoyerMDPhD #ACC2024 🫀🩸

[NEJM @NEJM]

Presented today at #ACC24:

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: https://t.co/3625asvzu8

[American College of Cardiology @ACCinTouch]

Read 10 key points to remember from a state-of-the-art review on the clinical impact, predictors, classification, and management of device-related thrombus after LAAO: https://t.co/JnQQwCkICC

[JACC Journals @JACCJournals]

This #JACCINT study delves into the incidence, predictors, and clinical impact of persistent and recurrent #DRT post #LAAO 📊⚠️ https://t.co/PgZV0Bf3yu

@benhibbertMDPhD @hsuradi @AshishPershad @caresans26 @rachelkaplanmd

[Conor Lane @DrConorLane]

Great insights from the great @keaglemd at the @MayoCVFellows Fellowship Education Day #cvPrev

[Dr. Apurva Bhavana Challa @ApurvaChalla]

Can deep learning be utilized to estimate LVEF from routine coronary angiographic images?

Read our latest publication https://t.co/UebsDy80ZA

[NEJM @NEJM]

In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: https://t.co/sHpHQFOGLu

#AHA23 @AHAScience